Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion. It may have areas that are morphologically similar to papillary renal cell carcinoma (RCC) type, or epithelial (tubular predominant) type Wilms' tumor. Prior immunohistochemical studies of MA have reported variable staining patterns. Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others. Recent microarray analysis of renal tumors has shown an increase of AMACR mRNA levels in papillary RCC but not in other subtypes. We investigated the utility of immunohistochemical staining for AMACR, cytokeratin 7(CK7), CD57 and WT1 to differentiate between the above-mentioned three neoplasms. Immunohistochemical stains were performed on paraffin-embedded tissue sections from 25 papillary RCC, 10 MAs and eight Wilms' tumors. AMACR was positive in one (10%) of 10 MAs and 24 (96%) of 25 papillary RCC, while it was negative in all Wilms' tumors. CK7 was positive in 20 of 25 papillary RCCs, focally positive in one Wilms' tumor and was negative in all MAs. CD57 was positive in all six MAs that were stained, focally positive in one of 25 papillary RCC and one of eight Wilms' tumors. WT1 was positive in seven of 10 MAs, three of 25 papillary RCCs and all eight Wilms' tumors. In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis. AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis. WT1 may be useful in separating Wilms' tumor from MA and papillary RCC but is not helpful in differentiating MA from papillary RCC.
Metanephric adenoma (MA) is a relatively rare though well-described benign neoplasm of the kidney. [1] [2] [3] [4] [5] [6] [7] The previously published series suggest that MAs are related to the proximal tubule of the fetal kidney or nephrogenic rests, and both the histologic and ultrastructural features of this tumor suggest similarities to metanephric tubular epithelium. 1, 8, 9 Morphologically, MA shares features with papillary renal cell carcinoma (PRCC) type I, particularly the solid variant 10 and the epithelial component of the epithelial (tubular predominant) type Wilms' tumor without anaplasia (WT). 11 Some genetic studies have suggested a close relationship between MA and PRCC by showing trisomies of chromosomes 7 and 17, and loss of sex chromosomes by classic cytogenetics 12 or FISH 13 in both, but others disagree, having found normal or variants of normal karyotypes in MA. 1, 2, 14 Most investigators now feel that these tumors are not genetically related. 15, 16 None of the studies have shown abnormalities of 11p in MA, as are seen in most syndromic and up to 15% of sporadic WT, arguing against a relationship with WT. 17 Tamas et al delineated a tumor suppressor gene on chromosome 2 in MA by microsatellite allelotyping, suggesting that MA is a genetic entity and is different from both WT and PRCC. 16 Prior immunohistochemical studies of MA have shown no consistent staining patterns. [1] [2] [3] Most tumors are reported to be negative for EMA with variable staining for cytokeratins. Positivity for CD57 (usually diffuse) 2, 18 and focal positivity for CK7 is often present. [1] [2] [3] 18 WT1 has also been reported to be positive. 2, 18 The WT gene WT1 encodes a protein that acts as a transcription activator and tumor suppressor and is thought to be essential in the development of embryonic kidney, ovaries and testes. 19 In renal tumors, WT1 expression is seen in Wilms' tumor, cystic partially differentiated nephroblastoma, rhabdoid tumor 20, 21 and MAs. 1, 18 CK7 is a type II (basic) keratin with a molecular weight of 54 kD. 22 It is known to be positive in tumors from various sites including most cases of PRCC. CD57 is a glycoprotein that is expressed on a wide variety of normal and neoplastic tissues; however, its function and biochemical activity are not known. 23 CD57 is expressed in the proximal tubules in the adult kidney. 21 Alpha-methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme 24, 25 that catalyzes the racemization of alpha-methyl, branched carboxylic coenzyme A thioesters. 26 Recently, several groups have shown that AMACR is potentially an important biomarker for prostate cancer. [27] [28] [29] It is overexpressed in tumors arising in other organ systems as well. 30 Recent DNA microarray studies found expression of high levels of AMACR in PRCC, but not in the other subtypes of RCC. [31] [32] [33] [34] The purpose of this study was to compare the immunophenotypic features of MA, WT and PRCC, and to evaluate an antibody panel that includes AMACR to aid in distinguishing them.
Materials and methods
In all, 10 MAs and eight nephroblastomas, epithelial (tubular predominant) type without anaplasia (WT) were identified from the files of Department of Pathology at the Memorial Sloan Kettering Cancer Center and from the consultation files of one of the authors (VER). A total of 25 low-grade (type I) PRCCs were retrieved from the department files of Memorial Sloan Kettering Cancer Center.
All original slides from each case were reviewed. Paraffin blocks or unstained slides (from the consultation cases) were available for all cases. Unstained 4 mm sections were cut from the paraffin block selected for each case and deparaffinized by routine techniques. Immunohistochemical stains were performed using the streptavidin-biotin peroxidase technique. Appropriate positive and negative control slides were stained in parallel.
Antibodies, their sources, their dilutions and pretreatments are listed in Table 1 .
The extent of immunolabeling was categorized into diffuse (staining in 50-100% of cells) or focal (staining in 5-50% of cells). The staining intensity of each case was scored as positive, weakly positive or negative. Thus, neoplasms scored as positive showed either diffuse or focal, strong nuclear staining for WT1 and/or strong cytoplasmic staining for AMACR, CD57 and CK7, while the tumors scored as weakly positive showed only faint cytoplasmic or nuclear labeling. Neoplasms scored as negative showed less than 5% of cells with cytoplasmic or nuclear staining for the abovementioned reagents.
Results
Microscopically MAs were usually unencapsulated but were sharply demarcated from the adjacent kidney parenchyma. The tumors were cellular with tightly packed acini, occasional tubules and solid areas ( Figure 1a) . 'Glomeruloid bodies' that are formed by the invagination of tumor cells into tubular lumina were observed in six cases. These structures frequently were associated with psammoma bodies. The cells had scant cytoplasm with round to oval uniform nuclei with delicate chromatin and inconspicuous nucleoli. No mitotic figures were present.
The papillary RCCs that were selected for this study were low-grade 'type I' tumors. A total of 10 cases were solid (glomeruloid) variants of PRCC and did not show true papillae but were composed of solid sheets of cells containing distinct micronodules that resembled abortive papillae. They had the appearance of the 'glomeruloid bodies' seen in MA, while other areas showed a tubular pattern. The remaining tumors predominantly showed a papillary growth pattern (Figure 1b ) with occasional aggregates of macrophages distending the fibrovascular cores. The cells lining the papilla and tubules as well as those forming the micronodules were similar, with scant to ample amphophilic to basophilic cytoplasm, vesicular nuclei, open chromatin and conspicuous to occasional prominent nucleoli.
All Wilms' tumors that were included in this study showed favorable histology with a triphasic pattern and a predominance of an epithelial component (Figure 1c) . The epithelial areas were com- Table 2 . Of the MAs, one of 10 was focally and weakly positive for AMACR while the remaining tumors were negative (Figure 2a ). The MA with AMACR positivity had neither glomeruloid pattern nor a significant papillary growth pattern. All MAs were negative for CK7 (Figure 3a) . Seven of the 10 MAs were focally positive (four cases weakly) for WT1 (Figure 4a ) and the remaining three were negative. All cases stained for antibody WT1 that contained normal kidney tissue showed nuclear immunoreactivity in the podocytes. Two of the three WT1-negative MAs did not contain adjacent normal tissue, so podocyte staining could not be evaluated. CD57 was diffusely and strongly positive in all six MAs (Figure 5a ) that had available material for staining. All but one PRCC were diffusely positive for AMACR (Figure 2b ) with 21 showing strong staining and three cases being weakly positive. CK7 was positive in 20 of 25 PRCCs (Figure 3b) . Five of these cases were weakly positive with focal positivity seen in nine cases. Only three out of 25 PRCCs were focally and weakly positive for WT1 while the other 22 cases were negative (Figure 4b ). CD57 was focally but strongly positive in only one PRCC and was negative in the remaining 24 cases (Figure 5b ). This tumor had a solid growth pattern and was positive for AMACR and negative for WT1. AMACR was negative in all WTs (Figure 2c ). Only one of the eight WTs was focally and weakly positive for CK7 in the epithelial component while the remaining seven cases were negative (Figure 3c ). WT1 was diffusely and strongly positive in all WTs ( Figure  4c ). CD57 was focally and strongly positive in the epithelial component of one WT (the same tumor with CK7 positivity) and was negative in the remaining seven tumors (Figure 5c ).
Discussion
The majority of the renal epithelial neoplasms can be diagnosed on the basis of morphology alone. However, examples of morphologic overlap exist between selected malignant and benign entities, as AMACR is an important immunohistochemical marker for the diagnosis of challenging prostate biopsies. [27] [28] [29] The expression of AMACR is not limited to the prostate since it is overexpressed in several malignant tumors of the colon, breast and ovary, among others. 30 Recently, DNA microarray studies [31] [32] [33] [34] found overexpression of AMACR in PRCC but not in other subtypes of renal tumors. AMACR has also been studied as an immunohistochemical marker in renal neoplasms. [32] [33] [34] Takahashi et al 33 reported strong AMACR positivity in 100% of their PRCCs and in only 10% of the conventional RCCs. All chromophobe RCCs were negative. Tretiakova et al 34 found an average of 5.2-fold increase in AMACR mRNA levels in PRCC while immunohistochemistry demonstrated strong AMACR positivity in all of PRCC but only focal or weak reactivity in the minority of other subtypes of RCC.
MA has morphologic similarity to some lowgrade (type I) PRCC and to WT. Several studies have evaluated the immunohistochemical staining pattern of MA with variable results. [1] [2] [3] 6 To our Racemase in metanephric adenoma S Olgac et al knowledge immunohistochemical expression of AMACR has not been studied to address this important differential diagnosis. We found AMACR to be positive in 96% of the papillary RCC, but only focally and weakly positive in 10% of the MAs, while negative in all WTs. These results suggest that it is a useful marker in the differential diagnosis of MA and PRCC. It is not helpful in differentiating MA from WT. The majority of the reported cases of MA have been negative for EMA, variably positive or negative for cytokeratins (AE1, AE1:AE3, high molecular weight cytokeratin), and usually focally positive for CK7. [1] [2] [3] 6, 18 However, in our study, similar to the results reported by Skinnider et al, 35 CK7 was negative in all MAs. The apparent discrepant result, when compared to the other published series, is due to different scoring systems used in various studies. For example Muir et al 18 have interpreted staining of o5% of the tumor cells as focally positive while we accepted less than 5% staining as negative. All seven reported cases 1, 18 of MA were strongly positive for WT1, while in our study only 70% of the cases were positive. We assume that technical reasons, including different clones for this antibody, are responsible for this variability in results. In the study by Muir et al 18 they have used the WT1 antibody clone 6F-H2 by Dako while we used clone 
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S Olgac et al C-19 12/30 by Santa Cruz. Prior studies have also reported CD57 (Leu 7) positivity in MA. 2, 18 Our study showed diffuse and strong positivity for CD57 in 100% of the cases stained, supporting the previously published observations.
Most type I PRCCs have been reported to be positive for CK7 and negative for WT1 and CD57. 18 In the current series, CK7 was positive in only 80% of PRCC, similar to the results of Skinnider et al 35 and Delahunt and Eble. 36 WT1 was positive in 12% and CD57 was focally positive in 4% of cases.
In our study, all but one WT (focal epithelial staining) were negative for CK7 and CD57 (focal epithelial staining) supporting the previously reported results. 18 In summary, even when used alone, AMACR appears to be a useful immunohistochemical marker for PRCC, and is a great adjunct in differentiating PRCC from MA. When used in combination with CK7 and CD57, AMACR will differentiate almost all MAs from PRCC. The combination of AMACR and WT1 is helpful in differentiating PRCC from WT. These immunohistochemical stains should be particularly useful in separating solid variants of PRCC from epithelial predominant WT. CD57, but not AMACR, is useful in the differential diagnosis between MA and WT.
